After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
The EMA rated each of the cities proposing to host the agency in terms of technical requirements (including building layouts and relocation planning), additional criteria (including accessibility of each location, resources for families of staffers, and business continuity), and the likelihood of retaining the most personnel. Vying for the EMA are Amsterdam, Netherlands; Athens, Greece; Barcelona, Spain; Bonn, Germany; Bratislava, Slovakia; Brussels, Belgium; Bucharest, Romania; Copenhagen, Denmark; Dublin, Ireland; Helsinki, Finland; Lille, France; Malta; Milan, Italy; Porto, Portugal; Sofia, Bulgaria; Stockholm, Sweden; Vienna, Austria; Warsaw, Poland; and Zagreb, Croatia.
The cities that earned top marks for meeting the EMA's technical requirements were the following:
Each of the above cities met some of the agency’s requirements, though the EMA had concerns about timely operation at each of the locations. Sofia and Malta earned the lowest ratings in this category.
In terms of its additional criteria, the EMA gave Vienna top marks, with Amsterdam, Barcelona, Copenhagen, Milan also ranked highly.
The cities in which the EMA was likely to retain 65% or more of its staff, based on feedback from its workers, were the following:
The cities where the agency could expect to retain less than 30% of its staff were the following:
While the EMA rated Barcelona highly in each of its categories, political unrest in Catalonia could take a toll on the city’s ability to secure the regulatory body's presence. Last week’s vote on independence for the Catalonia region was met with a show of Spanish police force that left hundreds of civilians injured. On Friday, Spain’s government began to ease restrictions on businesses seeking to leave Barcelona and other Catalonian areas in order to remain in the Eurozone in the event of a Catalonian secession; should Catalonia become an independent nation, it would not automatically retain membership in the European Union, and Barcelona could become just as untenable a long-term home for the EMA as London was.
The EMA has provided its report to the European Commission, which will determine the agency’s new location in a vote held next month.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.